Search

Your search keyword '"de Ramón, E"' showing total 132 results
Start Over Author "de Ramón, E"
132 results on '"de Ramón, E"'

3. Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients

Author

Cervera, R, Serrano, R, Pons-Estel, G J, Ceberio-Hualde, L, Shoenfeld, Y, de Ramón, E, Buonaiuto, V, Jacobsen, S, Zeher, M M, Tarr, T, Tincani, A, Taglietti, M, Theodossiades, G, Nomikou, E, Galeazzi, M, Bellisai, F, Meroni, P L, Derksen, R H W M, de Groot, P G D, Baleva, M, Mosca, M, Bombardieri, S, Houssiau, F, Gris, J-C, Quéré, I, Hachulla, E, Vasconcelos, C, Fernández-Nebro, A, Haro, M, Amoura, Z, Miyara, M, Tektonidou, M, Espinosa, G, Bertolaccini, M L, and Khamashta, M A

Published
2015
Full Text
View/download PDF

18. Morbidity and mortality in the antiphospholipid syndrome during a 10-year period : A multicentre prospective study of 1000 patients

Author

Cervera, R., Serrano, R., Pons-Estel, G. J., Ceberio-Hualde, L., Shoenfeld, Y., De Ramón, E., Buonaiuto, V., Jacobsen, S., Zeher, M. M., Tarr, T., Tincani, A., Taglietti, M., Theodossiades, G., Nomikou, E., Galeazzi, M., Bellisai, F., Meroni, P. L., Derksen, R. H W M, De Groot, P. G D, Baleva, M., Mosca, S., Bombardieri, M., Houssiau, F., Gris, J. C., Quéré, I., Hachulla, E., Vasconcelos, C., Fernández-Nebro, A., Haro, M., Amoura, Z., Miyara, M., Tektonidou, M., Espinosa, G., Bertolaccini, M. L., Khamashta, M. A., Cervera, R., Serrano, R., Pons-Estel, G. J., Ceberio-Hualde, L., Shoenfeld, Y., De Ramón, E., Buonaiuto, V., Jacobsen, S., Zeher, M. M., Tarr, T., Tincani, A., Taglietti, M., Theodossiades, G., Nomikou, E., Galeazzi, M., Bellisai, F., Meroni, P. L., Derksen, R. H W M, De Groot, P. G D, Baleva, M., Mosca, S., Bombardieri, M., Houssiau, F., Gris, J. C., Quéré, I., Hachulla, E., Vasconcelos, C., Fernández-Nebro, A., Haro, M., Amoura, Z., Miyara, M., Tektonidou, M., Espinosa, G., Bertolaccini, M. L., and Khamashta, M. A.

Published
2015

19. Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients

Author

UCL - SSS/IREC/RUMA - Pôle de Pathologies rhumatismales, UCL - (SLuc) Service de rhumatologie, Cervera, R, Serrano, R, Pons-Estel, G J, Ceberio-Hualde, L, Shoenfeld, Y, de Ramón, E, Buonaiuto, V, Jacobsen, S, Zeher, M M, Tarr, T, Tincani, A, Taglietti, M, Theodossiades, G, Nomikou, E, Galeazzi, M, Bellisai, F, Meroni, P L, Derksen, R H W M, de Groot, P G D, Baleva, M, Mosca, M, Bombardieri, S, Houssiau, Frédéric, Gris, J-C, Quéré, I, Hachulla, E, Vasconcelos, C, Fernández-Nebro, A, Haro, M, Amoura, Z, Miyara, M, Tektonidou, M, Espinosa, G, Bertolaccini, M L, Khamashta, M A, Euro-Phospholipid Project Group (European Forum on Antiphospholipid Antibodies), UCL - SSS/IREC/RUMA - Pôle de Pathologies rhumatismales, UCL - (SLuc) Service de rhumatologie, Cervera, R, Serrano, R, Pons-Estel, G J, Ceberio-Hualde, L, Shoenfeld, Y, de Ramón, E, Buonaiuto, V, Jacobsen, S, Zeher, M M, Tarr, T, Tincani, A, Taglietti, M, Theodossiades, G, Nomikou, E, Galeazzi, M, Bellisai, F, Meroni, P L, Derksen, R H W M, de Groot, P G D, Baleva, M, Mosca, M, Bombardieri, S, Houssiau, Frédéric, Gris, J-C, Quéré, I, Hachulla, E, Vasconcelos, C, Fernández-Nebro, A, Haro, M, Amoura, Z, Miyara, M, Tektonidou, M, Espinosa, G, Bertolaccini, M L, Khamashta, M A, and Euro-Phospholipid Project Group (European Forum on Antiphospholipid Antibodies)

Abstract

OBJECTIVES: To assess the prevalence of the main causes of morbi-mortality in the antiphospholipid syndrome (APS) during a 10-year-follow-up period and to compare the frequency of early manifestations with those that appeared later. METHODS: In 1999, we started an observational study of 1000 APS patients from 13 European countries. All had medical histories documented when entered into the study and were followed prospectively during the ensuing 10 years. RESULTS: 53.1% of the patients had primary APS, 36.2% had APS associated with systemic lupus erythematosus and 10.7% APS associated with other diseases. Thrombotic events appeared in 166 (16.6%) patients during the first 5-year period and in 115 (14.4%) during the second 5-year period. The most common events were strokes, transient ischaemic attacks, deep vein thromboses and pulmonary embolism. 127 (15.5%) women became pregnant (188 pregnancies) and 72.9% of pregnancies succeeded in having one or more live births. The most common obstetric complication was early pregnancy loss (16.5% of the pregnancies). Intrauterine growth restriction (26.3% of the total live births) and prematurity (48.2%) were the most frequent fetal morbidities. 93 (9.3%) patients died and the most frequent causes of death were severe thrombosis (36.5%) and infections (26.9%). Nine (0.9%) cases of catastrophic APS occurred and 5 (55.6%) of them died. The survival probability at 10 years was 90.7%. CONCLUSIONS: Patients with APS still develop significant morbidity and mortality despite current treatment. It is imperative to increase the efforts in determining optimal prognostic markers and therapeutic measures to prevent these complications.

Published
2015

20. Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: A multicentre prospective study of 1000 patients

Author

MS Reumatologie/Immunologie/Infectie, LKCH Overige medewerkers O&O, Cervera, R., Serrano, R., Pons-Estel, G. J., Ceberio-Hualde, L., Shoenfeld, Y., De Ramón, E., Buonaiuto, V., Jacobsen, S., Zeher, M. M., Tarr, T., Tincani, A., Taglietti, M., Theodossiades, G., Nomikou, E., Galeazzi, M., Bellisai, F., Meroni, P. L., Derksen, R. H W M, De Groot, P. G D, Baleva, M., Mosca, S., Bombardieri, M., Houssiau, F., Gris, J. C., Quéré, I., Hachulla, E., Vasconcelos, C., Fernández-Nebro, A., Haro, M., Amoura, Z., Miyara, M., Tektonidou, M., Espinosa, G., Bertolaccini, M. L., Khamashta, M. A., MS Reumatologie/Immunologie/Infectie, LKCH Overige medewerkers O&O, Cervera, R., Serrano, R., Pons-Estel, G. J., Ceberio-Hualde, L., Shoenfeld, Y., De Ramón, E., Buonaiuto, V., Jacobsen, S., Zeher, M. M., Tarr, T., Tincani, A., Taglietti, M., Theodossiades, G., Nomikou, E., Galeazzi, M., Bellisai, F., Meroni, P. L., Derksen, R. H W M, De Groot, P. G D, Baleva, M., Mosca, S., Bombardieri, M., Houssiau, F., Gris, J. C., Quéré, I., Hachulla, E., Vasconcelos, C., Fernández-Nebro, A., Haro, M., Amoura, Z., Miyara, M., Tektonidou, M., Espinosa, G., Bertolaccini, M. L., and Khamashta, M. A.

Published
2015

21. Morbidity and mortality in the antiphospholipid syndrome during a 10-year period:a multicentre prospective study of 1000 patients

Author

Cervera, R, Serrano, R, Pons-Estel, G J, Ceberio-Hualde, L, Shoenfeld, Y, de Ramón, E, Buonaiuto, V, Jacobsen, Søren, Zeher, M M, Tarr, T, Tincani, A, Taglietti, M, Theodossiades, G, Nomikou, E, Galeazzi, M, Bellisai, F, Meroni, P L, Derksen, R H W M, de Groot, P G D, Baleva, M, Mosca, M, Bombardieri, S, Houssiau, F, Gris, J-C, Quéré, I, Hachulla, E, Vasconcelos, C, Fernández-Nebro, A, Haro, M, Amoura, Z, Miyara, M, Tektonidou, M, Espinosa, G, Bertolaccini, M L, Khamashta, M A, Cervera, R, Serrano, R, Pons-Estel, G J, Ceberio-Hualde, L, Shoenfeld, Y, de Ramón, E, Buonaiuto, V, Jacobsen, Søren, Zeher, M M, Tarr, T, Tincani, A, Taglietti, M, Theodossiades, G, Nomikou, E, Galeazzi, M, Bellisai, F, Meroni, P L, Derksen, R H W M, de Groot, P G D, Baleva, M, Mosca, M, Bombardieri, S, Houssiau, F, Gris, J-C, Quéré, I, Hachulla, E, Vasconcelos, C, Fernández-Nebro, A, Haro, M, Amoura, Z, Miyara, M, Tektonidou, M, Espinosa, G, Bertolaccini, M L, and Khamashta, M A

Abstract

OBJECTIVES: To assess the prevalence of the main causes of morbi-mortality in the antiphospholipid syndrome (APS) during a 10-year-follow-up period and to compare the frequency of early manifestations with those that appeared later.METHODS: In 1999, we started an observational study of 1000 APS patients from 13 European countries. All had medical histories documented when entered into the study and were followed prospectively during the ensuing 10 years.RESULTS: 53.1% of the patients had primary APS, 36.2% had APS associated with systemic lupus erythematosus and 10.7% APS associated with other diseases. Thrombotic events appeared in 166 (16.6%) patients during the first 5-year period and in 115 (14.4%) during the second 5-year period. The most common events were strokes, transient ischaemic attacks, deep vein thromboses and pulmonary embolism. 127 (15.5%) women became pregnant (188 pregnancies) and 72.9% of pregnancies succeeded in having one or more live births. The most common obstetric complication was early pregnancy loss (16.5% of the pregnancies). Intrauterine growth restriction (26.3% of the total live births) and prematurity (48.2%) were the most frequent fetal morbidities. 93 (9.3%) patients died and the most frequent causes of death were severe thrombosis (36.5%) and infections (26.9%). Nine (0.9%) cases of catastrophic APS occurred and 5 (55.6%) of them died. The survival probability at 10 years was 90.7%.CONCLUSIONS: Patients with APS still develop significant morbidity and mortality despite current treatment. It is imperative to increase the efforts in determining optimal prognostic markers and therapeutic measures to prevent these complications.

Published
2015

22. Evaluation of the IL2/IL21, IL2RA and IL2RB genetic variants influence on the endogenous non-anterior uveitis genetic predisposition

Author

Cénit MC, Márquez A, Cordero-Coma M, Fonollosa A, Adán A, Martínez-Berriotxoa A, Llorenç V, Díaz Valle D, Blanco R, Cañal J, Díaz-Llopis M, García Serrano JL, de Ramón E, del Rio MJ, Begoña Gorroño-Echebarría M, Martín-Villa JM, Ortego-Centeno N, and Martín J

Subjects
stomatognathic diseases
Abstract

Recently, different genetic variants located within the IL2/IL21 genetic region as well as within both IL2RA and IL2RB loci have been associated to multiple autoimmune disorders. We aimed to investigate for the first time the potential influence of the IL2/IL21, IL2RA and IL2RB most associated polymorphisms with autoimmunity on the endogenous non-anterior uveitis genetic predisposition.

Published
2013

23. Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis

Author

Dooley, Ma, Jayne, D, Ginzler, Em, Isenberg, D, Olsen, Nj, Wofsy, D, Eitner, F, Appel, Gb, Contreras, G, Lisk, L, Solomons, N, Collaborators: Abud C, ALMS G. r. o. u. p., Adler, S, Alarc, G, Albuquerque, E, Almeida, F, Alvarellos, A, Appel, G, Avila, H, Menchaca, Ji, Blume, C, Boletis, I, Bonnardeaux, A, Braun, A, Buyon, J, Cervera, R, Chen, N, Chen, S, Da Costa AG, Davids, R, D'Cruz, D, De Ramón, E, Haya, C, Deodhar, A, Doria, Andrea, Dussol, B, Emery, P, Fiechtner, J, Floege, J, Fragoso Loyo, H, Furie, R, Ghazalli, R, Ghossein, C, Gilkeson, G, Ginzler, E, Grossman, J, Gu, J, Guillevin, L, Hatron, Py, Herrera, G, Hiepe, F, Houssiau, F, Hübscher, O, Hura, C, Kaplan, J, Kirsztajn, G, Kiss, E, Kutty, Ga, Laville, M, Lazaro, M, Lenz, O, Li, L, Lightstone, L, Lim, S, Malaise, M, Manzi, S, Marcos, J, Meyer, O, Bernard, C, Monge, P, Naicker, S, Neal, N, Neuwelt, M, Neuwelt, Cm, Nicholls, K, Olsen, N, Ordi Ros, J, Ostrov, B, Hershey, Ms, Pestana, M, Petri, M, Pokorny, G, Pourrat, J, Qian, J, Radhakrishnan, J, Rovin, B, Sánchez Guerrero, J, Sanchez Roman, J, Shanahan, J, Shergy, W, Skopouli, F, Spindler, A, Striebich, C, Sundel, R, Swanepoel, C, Tan, Sy, Tate, G, Tesaŕ, V, Tikly, M, Wang, H, Yahya, R, Yu, X, Zhang, F, Zoruba, D, Houssay, B, Carson, P, Snaith, M, and Cattran, D.

Published
2011

24. Nonrenal disease activity following mycophenolate mofetil or intravenous cyclophosphamide as induction treatment for lupus nephritis: findings in a multicenter, prospective, randomized, open-label, parallel-group clinical trial

Author

Ginzler, Em, Wofsy, D, Isenberg, D, Gordon, C, Lisk, L, Dooley, Ma, ALMS Group: Abud, C, Adler, S, Alarcón, G, Albuquerque, E, Almeida, F, Alvarellos, A, Appel, G, Avila, H, Blume, C, Boletis, I, Bonnardeaux, A, Braun, A, Buyon, J, Cervera, R, Chen, N, Chen, S, Contreras, G, Da Costa AG, Davids, R, D'Cruz, D, De Ramón, E, Deodhar, A, Doria, Andrea, Dussol, B, Emery, P, Fiechtner, J, Floege, J, Fragoso Loyo, H, Furie, R, Ghazalli, R, Ghossein, C, Gilkeson, G, Ginzler, E, Grossman, J, Gu, J, Guillevin, L, Hatron, Py, Herrera, G, Hiepe, F, Houssiau, F, Hübscher, O, Hura, C, Kaplan, J, Kirsztajn, G, Kiss, E, Kutty, Ga, Laville, M, Lazaro, M, Lenz, O, Li, L, Lightstone, L, Lim, S, Malaise, M, Manzi, S, Marcos, J, Meyer, O, Monge, P, Naicker, S, Neal, N, Neuwelt, M, Nicholls, K, Olsen, N, Ordi Ros, J, Ostrov, B, Pestana, M, Petri, M, Pokorny, G, Pourrat, J, Qian, J, Radhakrishnan, J, Rovin, B, Sanchez Guerrero, J, Roman, Js, Shanahan, J, Shergy, W, Skopouli, F, Spindler, A, Striebich, C, Sundel, R, Swanepoel, C, Tan, Sy, Tate, G, Tesar, V, Tikly, M, Wang, H, Yahya, R, Yu, X, Zhang, F, and Zoruba, D.

Subjects
Adult, Male, medicine.medical_specialty, Cyclophosphamide, Immunology, Lupus nephritis, Mycophenolate, Gastroenterology, Severity of Illness Index, Mycophenolic acid, law.invention, Rheumatology, Randomized controlled trial, Prednisone, law, Internal medicine, medicine, Immunology and Allergy, Humans, Pharmacology (medical), Prospective Studies, skin and connective tissue diseases, Glucocorticoids, business.industry, Anti-Inflammatory Agents, Non-Steroidal, Remission Induction, Complement System Proteins, Mycophenolic Acid, medicine.disease, Lupus Nephritis, Surgery, Clinical trial, Treatment Outcome, Antibodies, Antinuclear, Injections, Intravenous, Drug Therapy, Combination, Female, business, Immunosuppressive Agents, medicine.drug, Kidney disease
Abstract

To assess the effect of mycophenolate mofetil compared with intravenous pulses of cyclophosphamide on the nonrenal manifestations of lupus nephritis.Patients with active lupus nephritis (renal biopsy class III, IV, or V) were recruited for the study (n = 370) and treated with mycophenolate mofetil (target dosage 3 gm/day) or intravenous cyclophosphamide (0.5-1.0 gm/m(2)/month), plus tapered prednisone, for 24 weeks. Nonrenal outcomes were determined using measures of whole body disease activity, including the British Isles Lupus Assessment Group (BILAG) disease activity index, the Safety of Estrogens in Lupus Erythematosus: National Assessment (SELENA) version of the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI), and immunologic variables.Both treatments were effective on whole body disease activity in the systems examined, as indicated by changes in the classic BILAG index. With either treatment, remission was induced, notably in the mucocutaneous, musculoskeletal, cardiovascular/respiratory, and vasculitis systems, and flares were rare, as measured by the SELENA-SLEDAI. Levels of complement C3, C4, and CH50 and titers of anti-double-stranded DNA antibodies were normalized after treatment with either mycophenolate mofetil or intravenous cyclophosphamide.In addition to the efficacy of both treatments on the renal system, this analysis showed that remission could also be induced in other systems. There was no clear difference in efficacy between mycophenolate mofetil and intravenous cyclophosphamide in ameliorating either the renal or nonrenal manifestations. Mycophenolate mofetil is, therefore, a suitable alternative to cyclophosphamide for the treatment of renal and nonrenal disease manifestations in patients with biopsy-proven lupus nephritis.

Published
2010

25. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis

Author

Appel, Gb, Contreras, G, Dooley, Ma, Ginzler, Em, Isenberg, D, Jayne, D, Li, Ls, Mysler, E, Sánchez Guerrero, J, Solomons, N, Wofsy, D, Aspreva Lupus Management Study Group: Abud, C, Adler, S, Alarcón, G, Albuquerque, E, Almeida, F, Alvarellos, A, Appel, G, Avila, H, Blume, C, Boletis, I, Bonnardeaux, A, Braun, A, Buyon, J, Cervera, R, Chen, N, Chen, S, Da Costa AG, Davids, R, D'Cruz, D, De Ramón, E, Deodhar, A, Doria, Andrea, Dussol, B, Emery, P, Fiechtner, J, Floege, J, Fragoso Loyo, H, Furie, R, Ghazalli, R, Ghossein, C, Gilkeson, G, Ginzler, E, Gordon, C, Grossman, J, Gu, J, Guillevin, L, Hatron, Py, Herrera, G, Hiepe, F, Houssiau, F, Hübscher, O, Hura, C, Kaplan, J, Kirsztajn, G, Kiss, E, Kutty, Ga, Laville, M, Lazaro, M, Lenz, O, Li, L, Lightstone, L, Lim, S, Malaise, M, Manzi, S, Marcos, J, Meyer, O, Monge, P, Naicker, S, Neal, N, Neuwelt, M, Nicholls, K, Olsen, N, Ordi Ros, J, Ostrov, B, Pestana, M, Petri, M, Pokorny, G, Pourrat, J, Qian, J, Radhakrishnan, J, Rovin, B, Sanchez Roman, J, Shanahan, J, Shergy, W, Skopouli, F, Spindler, A, Striebich, C, Sundel, R, Swanepoel, C, Tan, Sy, Tate, G, Tesaŕ, V, Tikly, M, Wang, H, Yahya, R, Yu, X, Zhang, F, and Zoruba, D.

Subjects
Nephrology, Male, medicine.medical_specialty, Cyclophosphamide, Urology, Lupus nephritis, Renal function, Mycophenolic acid, Prednisone, Internal medicine, medicine, Ethnicity, Humans, Adverse effect, business.industry, Racial Groups, General Medicine, Mycophenolic Acid, medicine.disease, Lupus Nephritis, Surgery, Treatment Outcome, Injections, Intravenous, cardiovascular system, Female, business, Immunosuppressive Agents, medicine.drug, Kidney disease, Glomerular Filtration Rate
Abstract

Recent studies have suggested that mycophenolate mofetil (MMF) may offer advantages over intravenous cyclophosphamide (IVC) for the treatment of lupus nephritis, but these therapies have not been compared in an international randomized, controlled trial. Here, we report the comparison of MMF and IVC as induction treatment for active lupus nephritis in a multinational, two-phase (induction and maintenance) study. We randomly assigned 370 patients with classes III through V lupus nephritis to open-label MMF (target dosage 3 g/d) or IVC (0.5 to 1.0 g/m(2) in monthly pulses) in a 24-wk induction study. Both groups received prednisone, tapered from a maximum starting dosage of 60 mg/d. The primary end point was a prespecified decrease in urine protein/creatinine ratio and stabilization or improvement in serum creatinine. Secondary end points included complete renal remission, systemic disease activity and damage, and safety. Overall, we did not detect a significantly different response rate between the two groups: 104 (56.2%) of 185 patients responded to MMF compared with 98 (53.0%) of 185 to IVC. Secondary end points were also similar between treatment groups. There were nine deaths in the MMF group and five in the IVC group. We did not detect significant differences between the MMF and IVC groups with regard to rates of adverse events, serious adverse events, or infections. Although most patients in both treatment groups experienced clinical improvement, the study did not meet its primary objective of showing that MMF was superior to IVC as induction treatment for lupus nephritis.

Published
2009

26. European Working Party on Systemic Lupus Erythematosus. Systemic lupus erythematosus in Europe at the change of the millennium: lessons from the 'Euro-Lupus Project'

Author

Cervera, R, ABARCA COSTALAGO, M, Abramovicz, D, Allegri, F, Annunziata, P, Aydintug, Ao, Bacarelli, Mr, Bellisai, F, Bernardino, I, BIERNAT KALUZA, E, Blockmans, D, Boki, K, Bracci, L, Campanella, V, Camps, Mt, Carcassi, C, Cattaneo, Roberto, Cauli, A, CHWALINSKA SADOWSKA, H, Contu, L, Cosyns, Jp, Danieli, Mg, Dcruz, D, Depresseux, G, Direskeneli, H, Domènech, I, Espinosa, G, FERNÁNDEZ NEBRO, A, Ferrara, Gb, Font, J, Frutos, Ma, Galeazzi, M, GARCÌA CARRASCO, M, GARCÍA IGLESIAS MF, GARCÍA TOBARUELA, A, George, J, Gil, A, GONZÁLEZ SANTOS, P, Grana, M, Gül, A, Haga, Hj, DE HARO LIGER, M, Houssiau, F, Hughes, Gr, Ingelmo, M, JEDRYKA GÓRAL, A, Khamashta, Ma, Lavilla, P, Levi, Y, LÓPEZ DULPA, M, LÓPEZ SOTO, A, Maldykowa, H, Marcolongo, R, Mathieu, A, Morozzi, G, Nicolopoulou, N, Papasteriades, C, Passiu, G, Perelló, I, Petera, P, Petrovic, R, Piette, Jc, Pintado, V, DE PITA, O, Popovic, R, Pucci, G, Puddu, P, DE RAMÓN, E, RAMOS CASALS, M, RODRÍGUEZ ANDREU, J, RUIZ IRASTORZA, G, SANCHEZ LORA, J, Sanna, G, Scorza, R, Sebastiani, Gd, Sherer, Y, Shoenfeld, Y, Simpatico, A, Sinico, Ra, Smolen, J, Tincani, Angela, Tokgöz, G, URBANO MÁRQUEZ, A, Vasconcelos, C, Vázquez, Jj, Veronesi, J, Vianna, J, and Vivancos, J.

Published
2006

27. Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients

Author

Cervera, R, primary, Serrano, R, additional, Pons-Estel, G J, additional, Ceberio-Hualde, L, additional, Shoenfeld, Y, additional, de Ramón, E, additional, Buonaiuto, V, additional, Jacobsen, S, additional, Zeher, M M, additional, Tarr, T, additional, Tincani, A, additional, Taglietti, M, additional, Theodossiades, G, additional, Nomikou, E, additional, Galeazzi, M, additional, Bellisai, F, additional, Meroni, P L, additional, Derksen, R H W M, additional, de Groot, P G D, additional, Baleva, M, additional, Mosca, M, additional, Bombardieri, S, additional, Houssiau, F, additional, Gris, J-C, additional, Quéré, I, additional, Hachulla, E, additional, Vasconcelos, C, additional, Fernández-Nebro, A, additional, Haro, M, additional, Amoura, Z, additional, Miyara, M, additional, Tektonidou, M, additional, Espinosa, G, additional, Bertolaccini, M L, additional, and Khamashta, M A, additional

Published
2014
Full Text
View/download PDF

28. European Working Party on Systemic Lupus Erythematosus. Lessons from the 'Euro-Lupus Cohort'

Author

Cervera, R, ABARCA COSTALAGO, M, Abramovicz, D, Allegri, F, Annunziata, P, Aydintug, Ao, Bacarelli, Mr, Bellisai, F, Bernardino, I, BIERNAT KALUZA, E, Blockmans, D, Boki, K, Bracci, L, Campanella, V, Camps, Mt, Carcassi, C, Cattaneo, Roberto, Cauli, A, CHWALINSKA SADOWSKA, H, Contu, L, Cosyns, Jp, Danieli, Mg, D'Cruz, D, Depresseux, G, Direskeneli, H, Domènech, I, Espinosa, G, FERNÁNDEZ NEBRO, A, Ferrara, Gb, Font, J, Frutos, Ma, Galeazzi, M, GARCÍA CARRASCO, M, GARCÍA IGLESIAS MF, GARCÍA TOBARUELA, A, George, J, Gil, A, GONZÁLEZ SANTOS, P, Grana, M, Gül, A, Haga, Hj, DE HARO LIGER, M, Houssiau, F, Hughes, Gr, Ingelmo, M, JEDRYKA GÓRAL, A, Khamashta, Ma, Lavilla, P, Levi, Y, LÓPEZ DUPLA, M, LÓPEZ SOTO, A, Maldykowa, H, Marcolongo, R, Mathieu, A, Morozzi, G, Nicolopoulou, N, Papasteriades, C, Passiu, G, Perelló, I, Petera, P, Petrovic, R, Piette, Jc, Pintado, V, DE PITA, O, Popovic, R, Pucci, G, Puddu, P, DE RAMÓN, E, RAMOS CASALS, M, RODRÍGUEZ ANDREU, J, RUIZ IRASTROZA, G, SÁNCHEZ LORA, J, Sanna, G, Scorza, R, Sebastini, Gd, Sherer, Y, Shoenfeld, Y, Simpatico, A, Sinico, Ra, Smolen, J, Tincani, Angela, Tokgöz, G, URBANO MÁRQUEZ, A, Vasconcelos, C, Vázquez, Jj, Veronesi, M, Vianni, J, and Vivancos, J.

Published
2002

30. Systemic lupus erythematosus in Europe at the change of the millennium: Lessons from the 'Euro-Lupus Project'

Author

Cervera, R, Abarca Costalago, M, Abramovicz, D, Allegri, F, Annunziata, P, Aydintug, A, Bacarelli, M, Bellisai, F, Bernardino, I, Biernat Kaluza, E, Blockmans, D, Boki, K, Bracci, L, Campanella, V, Camps, M, Carcassi, C, Cattaneo, R, Cauli, A, Chwalinska Sadowska, H, Contu, L, Cosyns, J, Danieli, M, D́cruz, D, Depresseux, G, Direskeneli, H, Domènech, I, Espinosa, G, Fernández Nebro, A, Ferrara, G, Font, J, Frutos, M, Galeazzi, M, García Carrasco, M, García Iglesias, M, García Tobaruela, A, George, J, Gil, A, González Santos, P, Grana, M, Gül, A, Haga, H, de Haro Liger, M, Houssiau, F, Hughes, G, Ingelmo, M, Jedryka Góral, A, Khamashta, M, Lavilla, P, Levi, Y, López Dupla, M, López Soto, A, Maldykowa, H, Marcolongo, R, Mathieu, A, Morozzi, G, Nicolopoulou, N, Papasteriades, C, Passiu, G, Perelló, I, Petera, P, Petrovic, R, Piette, J, Pintado, V, de Pita, O, Popovic, R, Pucci, G, Puddu, P, de Ramón, E, Ramos Casals, M, Rodríguez Andreu, J, Ruiz Irastorza, G, Sánchez Lora, J, Sanna, G, Scorza, R, Sebastiani, G, Sherer, Y, Shoenfeld, Y, Simpatico, A, Sinico, R, Smolen, J, Tincani, A, Tokgöz, G, Urbano Márquez, A, Vasconcelos, C, Vázquez, J, Veronesi, M, Vianna, J, Vivancos, J, Vivancos, J., SINICO, RENATO ALBERTO, Cervera, R, Abarca Costalago, M, Abramovicz, D, Allegri, F, Annunziata, P, Aydintug, A, Bacarelli, M, Bellisai, F, Bernardino, I, Biernat Kaluza, E, Blockmans, D, Boki, K, Bracci, L, Campanella, V, Camps, M, Carcassi, C, Cattaneo, R, Cauli, A, Chwalinska Sadowska, H, Contu, L, Cosyns, J, Danieli, M, D́cruz, D, Depresseux, G, Direskeneli, H, Domènech, I, Espinosa, G, Fernández Nebro, A, Ferrara, G, Font, J, Frutos, M, Galeazzi, M, García Carrasco, M, García Iglesias, M, García Tobaruela, A, George, J, Gil, A, González Santos, P, Grana, M, Gül, A, Haga, H, de Haro Liger, M, Houssiau, F, Hughes, G, Ingelmo, M, Jedryka Góral, A, Khamashta, M, Lavilla, P, Levi, Y, López Dupla, M, López Soto, A, Maldykowa, H, Marcolongo, R, Mathieu, A, Morozzi, G, Nicolopoulou, N, Papasteriades, C, Passiu, G, Perelló, I, Petera, P, Petrovic, R, Piette, J, Pintado, V, de Pita, O, Popovic, R, Pucci, G, Puddu, P, de Ramón, E, Ramos Casals, M, Rodríguez Andreu, J, Ruiz Irastorza, G, Sánchez Lora, J, Sanna, G, Scorza, R, Sebastiani, G, Sherer, Y, Shoenfeld, Y, Simpatico, A, Sinico, R, Smolen, J, Tincani, A, Tokgöz, G, Urbano Márquez, A, Vasconcelos, C, Vázquez, J, Veronesi, M, Vianna, J, Vivancos, J, Vivancos, J., and SINICO, RENATO ALBERTO

Abstract

The "Euro-Lupus Cohort" is composed by 1000 patients with systemic lupus erythematosus (SLE) that have been followed prospectively since 1991. These patients have been gathered by a European consortium-the "Euro-Lupus Project Group". This consortium was originated as part of the network promoted by the "European Working Party on SLE", a working group created in 1990 in order to promote research in Europe on the different problems related to this disease. The "Euro-Lupus Cohort" provides an updated information on the SLE morbidity and mortality characteristics in the present decade as well as defines several clinical and immunological prognostic factors. © 2005 Elsevier B.V. All rights reserved.

Published
2006

31. Lessons from the 'Euro-Lupus Cohort'

Author

Cervera, R, Abarca Costalago, M, Abramovicz, D, Allegri, F, Annunziata, P, Aydintug, A, Bacarelli, M, Bellisai, F, Bernardino, I, Biernat Kaluza, E, Blockmans, D, Boki, K, Bracci, L, Campanella, V, Camps, M, Carcassi, C, Cattaneo, R, Cauli, A, Chwalinska Sadowska, H, Contu, L, Cosyns, J, Danieli, M, D'Cruz, D, Depresseux, G, Direskeneli, H, Domènech, I, Espinosa, G, Fernández Nebro, A, Ferrara, G, Font, J, Frutos, M, Galeazzi, M, García Carrasco, M, García Iglesias, M, García Tobaruela, A, George, J, Gil, A, González Santos, P, Grana, M, Gül, A, Haga, H, de Haro Liger, M, Houssiau, F, Hughes, G, Ingelmo, M, Jedryka Góral, A, Khamashta, M, Lavilla, P, Levi, Y, López Dupla, M, López Soto, A, Maldykowa, H, Marcolongo, R, Mathieu, A, Morozzi, G, Nicolopoulou, N, Papasteriades, C, Passiu, G, Perelló, I, Petera, P, Petrovic, R, Piette, J, Pintado, V, de Pita, O, Popovic, R, Pucci, G, Puddu, P, de Ramón, E, Ramos Casals, M, Rodríguez Andreu, J, Ruiz Irastroza, G, Sánchez Lora, J, Sanna, G, Scorza, R, Sebastini, G, Sherer, Y, Shoenfeld, Y, Simpatico, A, Sinico, R, Smolen, J, Tincani, A, Tokgöz, G, Urbano Márquez, A, Vasconcelos, C, Vázquez, J, Veronesi, M, Vianni, J, Vivancos, J, SINICO, RENATO ALBERTO, Vivancos, J., Cervera, R, Abarca Costalago, M, Abramovicz, D, Allegri, F, Annunziata, P, Aydintug, A, Bacarelli, M, Bellisai, F, Bernardino, I, Biernat Kaluza, E, Blockmans, D, Boki, K, Bracci, L, Campanella, V, Camps, M, Carcassi, C, Cattaneo, R, Cauli, A, Chwalinska Sadowska, H, Contu, L, Cosyns, J, Danieli, M, D'Cruz, D, Depresseux, G, Direskeneli, H, Domènech, I, Espinosa, G, Fernández Nebro, A, Ferrara, G, Font, J, Frutos, M, Galeazzi, M, García Carrasco, M, García Iglesias, M, García Tobaruela, A, George, J, Gil, A, González Santos, P, Grana, M, Gül, A, Haga, H, de Haro Liger, M, Houssiau, F, Hughes, G, Ingelmo, M, Jedryka Góral, A, Khamashta, M, Lavilla, P, Levi, Y, López Dupla, M, López Soto, A, Maldykowa, H, Marcolongo, R, Mathieu, A, Morozzi, G, Nicolopoulou, N, Papasteriades, C, Passiu, G, Perelló, I, Petera, P, Petrovic, R, Piette, J, Pintado, V, de Pita, O, Popovic, R, Pucci, G, Puddu, P, de Ramón, E, Ramos Casals, M, Rodríguez Andreu, J, Ruiz Irastroza, G, Sánchez Lora, J, Sanna, G, Scorza, R, Sebastini, G, Sherer, Y, Shoenfeld, Y, Simpatico, A, Sinico, R, Smolen, J, Tincani, A, Tokgöz, G, Urbano Márquez, A, Vasconcelos, C, Vázquez, J, Veronesi, M, Vianni, J, Vivancos, J, SINICO, RENATO ALBERTO, and Vivancos, J.

Abstract

The "Euro-Lupus Cohort" is composed by 1,000 patients with systemic lupus erythematosus (SLE) that have been followed prospectively since 1991. These patients have been gathered by a European consortium - the "Euro-Lupus Project Group". This consortium was originated as part of the network promoted by the "European Working Party on SLE", a working group created in 1990 in order to promote research in Europe on the different problems related to this disease. The "Euro-Lupus Cohort" provides an updated information on the SLE morbidity and mortality characteristics in the present decade as well as defines several clinical and immunological prognostic factors

Published
2002

32. No evidence for genetic association of interferon regulatory factor 3 in systemic lupus erythematosus

Author

Sánchez, E, primary, González-Gay, MA, additional, Callejas-Rubio, JL, additional, Ortego-Centeno, N, additional, Sabio, JM, additional, Jiménez-Alonso, J, additional, Micó, L, additional, Suarez, A, additional, Gutierrez, C, additional, de Ramón, E, additional, Camps, M, additional, Garcia-Portales, R, additional, Tolosa, C, additional, López-Nevot, MA, additional, Sánchez-Román, J, additional, Hernández, FJ, additional, González-Escribano, MF, additional, and Martín, J, additional

Published
2009
Full Text
View/download PDF

33. Study of a functional polymorphism in thep53 gene in systemic lupus erythematosus: lack of replication in a Spanish population

Author

Sánchez, E, primary, Sabio, J M, additional, Callejas, J L, additional, de Ramón, E, additional, de Haro, M, additional, Jiménez-Alonso, J, additional, Ortego-Centeno, N, additional, Sánchez-Román, J, additional, González-Gay, M A, additional, López-Nevot, M A, additional, González-Escribano, M F, additional, and Martín, J, additional

Published
2006
Full Text
View/download PDF

35. Study of a functional polymorphism in the p53 gene in systemic lupus erythematosus: lack of replication in a Spanish population.

Author

Sánchez, E., Sabio, J. M., Callejas, J. L., de Ramón, E., de Haro, M., Jiménez-Alonso, J., Ortego-Centeno, N., Sánchez-Román, J., González-Gay, M. A., López-Nevot, M. A., González-Escribano, M. F., and Martín, Javier

Subjects
P53 antioncogene, SYSTEMIC lupus erythematosus, AUTOIMMUNE diseases, GENETIC polymorphisms, DISEASE susceptibility, SENSITIVITY (Personality trait)
Abstract

The aim of this study was to assess the possible association between the p53 suppressor gene codon 72 polymorphism and systemic lupus erythematosus (SLE). Our study population consisted of 513 SLE patients and 567 healthy controls. All the individuals were of Spanish Caucasian origin. Genotyping of the p53 codon 72 polymorphism was performed by allele-specific PCR. No statistically significant differences were observed between SLE patients and healthy controls when p53 codon 72 genotype and allele frequencies were compared. In addition, no evidence for association with clinical subfeatures of SLE was found. In conclusion, the p53 codon 72 polymorphism associated with SLE in a Korean population does not appear to play a major role in the susceptibility or severity of SLE in the Spanish population. [ABSTRACT FROM AUTHOR]

Published
2006
Full Text
View/download PDF

36. Systemic lupus erythematosus in southern Spain: a comparative clinical and genetic study between Caucasian and Gypsy patients.

Author

Ramal, L.M., López-Nevot, M.A., Sabio, J.M., Jáimez, L., Paco, L, Sánchez, J, de Ramón, E, Fernández-Nebro, A, Ortego, N, Ruiz-Cantero, A, Rivera, F, Martín, J, and Jim&énez-Alonso, J

Subjects
SYSTEMIC lupus erythematosus, SKIN diseases, PROTEIN S deficiency, BLOOD coagulation, CARDIOVASCULAR diseases, ETHNIC groups, DERMATOLOGY
Abstract

We evaluated the influence of the hereditary make-up on the development of systemic lupus erythematosus (SLE) in two ethnic groups [Gypsy and white Caucasian Mediterranean (WCM) populations], living in the same geographic area. We compared 81 WCM and 25 Gypsy patients with SLE. The control group consisted of 185 healthy unrelated individuals, 105 WC and 80 Gypsies. In the Gypsy population, the onset of SLE occurred at earlier ages than in the other ethnic group (25.9 versus 32.0 years, P = 0.02), and showed lower SLEDAI peak values (4.9 versus 7.0, P = 0.016). The frequency of joint, kidney, gastrointestinal and eye involvement was significantly lower in Gypsy patients. In contrast, SLE-associated antiphospholipid syndrome, thrombosis and livedo reticularis were more frequent in Gypsies than in the majority ethnic group (WCM). In WCM patients, DRB1*1303– DQB1*0301 haplotype was associated with SLE (P = 0.001, Pc = 0.038). We found SLE to be associated with DR5 (P = 0.006, Pc = 0.05) in the Gypsy population as well as a protective effect of DPB1*0401 when DR5 was not present (P = 0.008, Pc = 0.032). In conclusion, we found some clinical differences between WCM and Gypsy patients with SLE. Furthermore, HLA associations between HLA – DRB1 –DQB1 and SLE were different for Gypsy people. [ABSTRACT FROM AUTHOR]

Published
2004
Full Text
View/download PDF

37. Quality of life in multiple sclerosis patients in Spain.

Author

Chang, C-H, Cella, D, Fernández, O, Luque, G, de Castro, P, de Andrés, C, Casanova, B, Hernández, M A, Prieto, J M, Fernández, V E, and de Ramón, E

Subjects
PSYCHOMETRICS, MULTIPLE sclerosis, PATIENTS, QUALITY of life
Abstract

Objective: The cross-sectional study evaluated the psychometric properties of the Functional Assessment of Multiple Sclerosis (FAMS) Spanish version and its use in measuring quality of life (QOL) of multiple sclerosis (MS) patients in Spain. Methods: The FAMS is a factorially derived self-report scale designed to assess six primary aspects of QOL of patients with MS: Mobility, Symptoms, Emotional Well-Being, General Contentment, Thinking and Fatigue, and Family/Social Well-Being. Its Spanish translated version was used to assess QOL of 625 MS patients recruited in an outpatient clinic setting from 58 hospitals in Spain. Internal consistency of the Spanish FAMS was evaluated. Multiple regression analyses were performed to identify significant predictors from demographic, clinical and treatment characteristics, and Kurtzke Expanded Disability Status Scale (EDSS) scores in predicting FAMS scale scores. Results: Most of the patients are females (66%), and 74% were of the relapsing-remitting (RR) clinical subtype. Cronbach's alpha coefficients were high (range=0.78–0.96), indicating subscale homogeneity comparable to that of the original English version. Linear multivariate regression analyses revealed that the EDSS is a dominant variable in predicting all the FAMS subscales, especially mobility (R[sup 2]=0.51) and the total scores. Conclusions: The Spanish FAMS is a psychometrically valid instrument that allows clinicians and clinical researchers the ability to measure the QOL concerns of MS patients in Spain. [ABSTRACT FROM AUTHOR]

Published
2002
Full Text
View/download PDF

41. Investigation of TLR5 and TLR7 as candidate genes for susceptibility to systemic lupus erythematosus

Author

Elena Sanchez, Jl, Callejas-Rubio, Jm, Sabio, Ma, Gónzalez-Gay, Jimenez-Alonso J, Micó L, de Ramón E, Camps M, Suarez A, Gutierrez C, Garcia-Portales R, Tolosa C, Ortego-Centeno N, Sánchez-Román J, Fj, Garcia-Hernández, Mf, Gónzalez-Escribano, and Martin J

Subjects
Toll-Like Receptor 5, Toll-Like Receptor 7, Case-Control Studies, Odds Ratio, Humans, Lupus Erythematosus, Systemic, Genetic Predisposition to Disease, Polymorphism, Single Nucleotide, White People
Abstract

The aim of this study was to evaluate the relevance of genetic variants of TLR5 (rs5744168) and TLR7 (rs179008) gene in systemic lupus erythematosus (SLE) in a Spanish population.Our study population consisted of 752 SLE patients and 1107 healthy controls. All individual were of Spanish Caucasian origin. The TLR5 and TLR7 polymorphisms were genotyped using a PCR system with pre-developed TaqMan allelic discrimination assay.No statistically significant differences were observed when the allele and genotype distribution of TLR5 rs5744168 and TLR7 rs179008 polymorphisms was compared between SLE patients and healthy controls. A significant increase frequency in the CC genotype of the TLR5 rs5744168 polymorphism among SLE patients without nephritis was found (93% vs. 87% in SLE patients with nephritis, p=0.03, OR=2.11 95%CI 0.93-3.51). However, this difference did not reach statistical significance in the allele frequencies (p=0.08).These results suggest that the tested variations of TLR5 and TLR7 genes do not confer a relevant role in the susceptibility or severity to SLE in the Spanish population.

45. Analysis of ancestral and functionally relevant CD5 variants in systemic lupus erythematosus patients

Author

Miguel A. González-Gay, María Carmen Cenit, Mario Martínez-Florensa, Carles Tolosa, Noelia Armiger, Ana Suárez, Francisco Hernandez, Elena Carnero-Montoro, Javier Martín, Francisco Lozano, Norberto Ortego-Centeno, Enrique de Ramón, Elena Bosch, Miguel Caballero-Baños, M.T. Arias, José Mario Sabio, Daniel Benitez, Marta Consuegra, Lizette Bonet, Universidad de Cantabria, Universitat de Barcelona, Ministerio de Economía y Competitividad (España), Generalitat de Catalunya, Junta de Andalucía, European Commission, Instituto de Salud Carlos III, [Cenit,MC, Martín,J] Instituto de Parasitología y Biomedicina López-Neyra, Consejo Superior de Investigaciones Científicas (CSIC), Granada, Spain. [Martínez-Florensa,M] ImmunNovative Developments, Barcelona, Spain. [Martínez-Florensa,M, Consuegra,M, Bonet,L, Armiger,N, Benitez,D, Lozano,F] Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain. [Carnero-Montoro,E, Bosch,L] Institut de Biologia Evolutiva (CSIC-Universitat Pompeu Fabra), Departament de Ciències Experimentals i de la Salut, Parc de Recerca Biomèdica de Barcelona, Barcelona, Spain. [Caballero-Baños,M, Arias,MT, Lozano,F] Department of Immunology, Hospital Clínic de Barcelona, Barcelona, Spain. [Ortego-Centeno,N] Department of Internal Medicine, Hospital Clínico San Cecilio, Granada, Spain. [de Ramón,E] Department of Internal Medicine, Hospital Carlos Haya, Málaga, Spain. [Sabio,JM] Department of Internal Medicine, Hospital Virgen de las Nieves, Granada, Spain. [García–Hernández,FJ] Department of Internal Medicine, Hospital Virgen del Rocío, Seville, Spain. [Tolosa,C] Department of Internal Medicine, Hospital Parc Taulí, Sabadell, Spain. [Suárez,A] Department of Functional Biology, Immunology Area, Faculty of Medicine, University of Oviedo, Oviedo, Spain. [González-Gay,MA] Department of Rheumatology, Hospital Marques de Valdecilla, IFIMAV, Santander, Spain. [Lozano,F] Departament de Biologia Cel•lular, Immunologia i Neurociencies, Facultat de Medicina, Universitat de Barcelona, Barcelona, Spain., and This work was supported by grants from the Spanish Ministerio de Economía y Competitividad [SAF2010-19717 to FL, SAF2009-11110 to JM, SAF2011-29239, and BFU2008-01046 to EB], Generalitat de Catalunya [2009SGR00252 to FL, and 2009SGR1101 to EB], Junta de Andalucı´a [CTS-4977], and Instituto de Salud Carlos III and Fondo Europeo de Desarrollo Regional/FEDER [RD12/0009/0004 to JM]

Subjects
Phenomena and Processes::Immune System Phenomena::Immunity::Autoimmunity [Medical Subject Headings], Diseases::Immune System Diseases::Autoimmune Diseases::Lupus Erythematosus, Systemic::Lupus Nephritis [Medical Subject Headings], T-Lymphocytes, Lymphocyte, Lupus nephritis, Polimorfismo genético, Autoimmunity, Lymphocyte Activation, medicine.disease_cause, Phenomena and Processes::Genetic Phenomena::Genotype::Haplotypes [Medical Subject Headings], Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings], immune system diseases, Nefritis lúpica, Medicine and Health Sciences, Lupus Erythematosus, Systemic, Immunologia, Lymphocytes, Genetics, Multidisciplinary, Estudios de casos y controles, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Epidemiologic Study Characteristics as Topic::Epidemiologic Studies::Case-Control Studies [Medical Subject Headings], Diseases::Immune System Diseases::Autoimmune Diseases::Lupus Erythematosus, Systemic [Medical Subject Headings], Predisposición genética a la enfermedad, Lupus Nephritis, Humanos, medicine.anatomical_structure, Medicine, Haplotipos, Phenomena and Processes::Genetic Phenomena::Genotype [Medical Subject Headings], Alelos, Nephritis, Research Article, Genotype, Inflammatory Diseases, T cell, Science, Immunology, Antígenos CD5, Single-nucleotide polymorphism, Autoinmunidad, CD5 Antigens, Limfòcits, Diseases::Pathological Conditions, Signs and Symptoms::Pathologic Processes::Disease Attributes::Disease Susceptibility::Genetic Predisposition to Disease [Medical Subject Headings], Rheumatology, Lupus eritematós sistèmic, Lupus eritematoso sistémico, medicine, Humans, Genetic Predisposition to Disease, Allele, Phenomena and Processes::Genetic Phenomena::Genetic Structures::Genome::Genome Components::Genes::Alleles [Medical Subject Headings], Alleles, Polymorphism, Genetic, Lupus erythematosus, Chemicals and Drugs::Amino Acids, Peptides, and Proteins::Proteins::Glycoproteins::Membrane Glycoproteins::Antigens, CD58 [Medical Subject Headings], business.industry, Haplotype, Biology and Life Sciences, Phenomena and Processes::Genetic Phenomena::Genetic Variation::Polymorphism, Genetic [Medical Subject Headings], medicine.disease, Haplotypes, Case-Control Studies, Lupus eritematós, business, Genotipo
Abstract

Cénit, M.C. et al., CD5 plays a crucial role in autoimmunity and is a well-established genetic risk factor of developing RA. Recently, evidence of positive selection has been provided for the CD5 Pro224-Val471 haplotype in East Asian populations. The aim of the present work was to further analyze the functional relevance of non-synonymous CD5 polymorphisms conforming the ancestral and the newly derived haplotypes (Pro224-Ala471 and Pro224-Val471, respectively) as well as to investigate the potential role of CD5 on the development of SLE and/or SLE nephritis, This work was supported by grants from the Spanish Ministerio de Economía y Competitividad [SAF2010-19717 to FL, SAF2009-11110 to JM, SAF2011-29239, and BFU2008-01046 to EB], Generalitat de Catalunya [2009SGR00252 to FL, and 2009SGR1101 to EB], Junta de Andalucía [CTS-4977], and Instituto de Salud Carlos III and Fondo Europeo de Desarrollo Regional/FEDER [RD12/0009/0004 to JM].

Published
2014

46. Lessons from the 'Euro-Lupus Cohort'

Author

Cervera, R., Abarca Costalago, M., Abramovicz, D., Allegri, F., PASQUALE ANNUNZIATA, Aydintug, Ao, Bacarelli, Mr, Bellisai, F., Bernardino, I., Biernat Kaluza, E., Blockmans, D., Boki, K., LUISA BRACCI, Campanella, V., Camps, Mt, Carcassi, C., Cattaneo, R., Cauli, A., Chwalinska Sadowska, H., Contu, L., Cosyns, Jp, Danieli, Mg, D Cruz, D., Depresseux, G., Direskeneli, H., Domènech, I., Espinosa, G., Fernández Nebro, A., Ferrara, Gb, Font, J., Frutos, Ma, MAURO GALEAZZI, García Carrasco, M., GARCÍA IGLESIAS MF, García Tobaruela, A., George, J., Gil, A., González Santos, P., Grana, M., Gül, A., Haga, Hj, Haro Liger, M., Houssiau, F., Hughes, Gr, Ingelmo, M., Jedryka Góral, A., Khamashta, Ma, Lavilla, P., Levi, Y., López Dupla, M., López Soto, A., Maldykowa, H., Marcolongo, R., Mathieu, A., GABRIELLA MOROZZI, Nicolopoulou, N., Papasteriades, C., Passiu, G., Perelló, I., Petera, P., Petrovic, R., Piette, Jc, Pintado, V., Pita, O., Popovic, R., Pucci, G., Puddu, P., Ramón, E., Ramos Casals, M., Rodríguez Andreu, J., Ruiz Irastroza, G., Sánchez Lora, J., Sanna, G., Scorza, R., Sebastini, Gd, Sherer, Y., Shoenfeld, Y., Simpatico, A., Sinico, Ra, Smolen, J., Tincani, A., Tokgöz, G., Urbano Márquez, A., Vasconcelos, C., Vázquez, Jj, Veronesi, M., Vianni, J., Vivancos, J., EUROPEAN WORKING PARTY ON SYSTEMIC LUPUS ERYTHEMATOSUS, Cervera, R, Abarca Costalago, M, Abramovicz, D, Allegri, F, Annunziata, P, Aydintug, A, Bacarelli, M, Bellisai, F, Bernardino, I, Biernat Kaluza, E, Blockmans, D, Boki, K, Bracci, L, Campanella, V, Camps, M, Carcassi, C, Cattaneo, R, Cauli, A, Chwalinska Sadowska, H, Contu, L, Cosyns, J, Danieli, M, D'Cruz, D, Depresseux, G, Direskeneli, H, Domènech, I, Espinosa, G, Fernández Nebro, A, Ferrara, G, Font, J, Frutos, M, Galeazzi, M, García Carrasco, M, García Iglesias, M, García Tobaruela, A, George, J, Gil, A, González Santos, P, Grana, M, Gül, A, Haga, H, de Haro Liger, M, Houssiau, F, Hughes, G, Ingelmo, M, Jedryka Góral, A, Khamashta, M, Lavilla, P, Levi, Y, López Dupla, M, López Soto, A, Maldykowa, H, Marcolongo, R, Mathieu, A, Morozzi, G, Nicolopoulou, N, Papasteriades, C, Passiu, G, Perelló, I, Petera, P, Petrovic, R, Piette, J, Pintado, V, de Pita, O, Popovic, R, Pucci, G, Puddu, P, de Ramón, E, Ramos Casals, M, Rodríguez Andreu, J, Ruiz Irastroza, G, Sánchez Lora, J, Sanna, G, Scorza, R, Sebastini, G, Sherer, Y, Shoenfeld, Y, Simpatico, A, Sinico, R, Smolen, J, Tincani, A, Tokgöz, G, Urbano Márquez, A, Vasconcelos, C, Vázquez, J, Veronesi, M, Vianni, J, and Vivancos, J

Subjects
Adult, Male, Adolescent, Prognosi, Middle Aged, Prognosis, Cohort Studies, Europe, Survival Rate, Prospective Studie, Antibodies, Antinuclear, Humans, Lupus Erythematosus, Systemic, Female, Prospective Studies, Cohort Studie, Age of Onset, Human
Abstract

The "Euro-Lupus Cohort" is composed by 1,000 patients with systemic lupus erythematosus (SLE) that have been followed prospectively since 1991. These patients have been gathered by a European consortium - the "Euro-Lupus Project Group". This consortium was originated as part of the network promoted by the "European Working Party on SLE", a working group created in 1990 in order to promote research in Europe on the different problems related to this disease. The "Euro-Lupus Cohort" provides an updated information on the SLE morbidity and mortality characteristics in the present decade as well as defines several clinical and immunological prognostic factors.

Published
2002

47. Effect of ethnicity on clinical presentation and risk of antiphospholipid syndrome in Roma and Caucasian patients with systemic lupus erythematosus: a multicenter cross-sectional study.

Author

Manzano-Gamero V, Pardo-Cabello AJ, Vargas-Hitos JA, Zamora-Pasadas M, Navarrete-Navarrete N, Sabio JM, Jáimez-Gámiz L, Ríos-Fernandez R, Ortego-Centeno N, Ayala-Gutierrez MM, de Ramón E, Colodro-Ruíz A, Micó-Giner L, Castillo-Palma MJ, Robles-Marhuenda Á, Luna-Del Castillo JD, and Jiménez-Alonso J

Subjects
Abortion, Spontaneous ethnology, Adolescent, Adult, Antibodies, Antiphospholipid blood, Antiphospholipid Syndrome blood, Antiphospholipid Syndrome diagnosis, Antiphospholipid Syndrome immunology, Biomarkers blood, Comorbidity, Cross-Sectional Studies, Female, Fetal Death, Humans, Lupus Erythematosus, Systemic blood, Lupus Erythematosus, Systemic diagnosis, Lupus Erythematosus, Systemic immunology, Male, Middle Aged, Pregnancy, Prevalence, Risk Assessment, Risk Factors, Spain epidemiology, Thrombosis ethnology, Young Adult, Antiphospholipid Syndrome ethnology, Lupus Erythematosus, Systemic ethnology, Roma, White People
Abstract

Aim: To determine if there are ethnic differences in the prevalence of antiphospholipid syndrome (APS), clinical presentation and autoantibody profile between Roma and Caucasian patients with systemic lupus erythematosus (SLE)., Method: A cross-sectional study was conducted including data from Roma and Caucasian SLE patients consecutively attending six hospitals in Spain. Socio-demographic characteristics, prevalence of APS, clinical and analytical features of SLE and APS were compared between ethnic groups., Results: Data from 52 Roma and 98 Caucasian SLE patients were included. Roma SLE patients had a higher risk (odds ratio 2.56, 95% CI 1.02-6.39) and prevalence of APS (28.8% vs. 13.3%, P = 0.027). Furthermore, Roma SLE patients had a statistically significant higher prevalence of abortions (23.5% vs. 10.2%, P = 0.049). In relation to other APS diagnostic criteria, Roma SLE patients had a non-statistically significant higher prevalence of fetal deaths (14.3% vs. 5.1%, P = 0.106) and thrombotic events (21.1% vs. 12.2%, P = 0.160). In relation to SLE clinical features, Roma patients had a significantly higher prevalence of arthritis (75% vs. 57.1%, P = 0.034) and non-significant higher prevalence of serositis (44.2% vs. 29.6%, P = 0.104), discoid lesions (11.5% vs. 5.1%, P = 0.191), oral ulcers (46.1% vs. 34.7%, P = 0.218) and livedo reticularis (21.1% vs. 15.3%, P = 0.374). No statistically significant differences were found in the Systemic Lupus International Collaborating Clinics Damage Index or the autoimmune serological profile., Conclusion: Prevalence and risk of APS were significantly higher in Roma SLE patients. Furthermore, Roma patients had a significantly higher prevalence of abortions and a non-significant higher prevalence of fetal deaths and thrombotic events., (© 2017 Asia Pacific League of Associations for Rheumatology and John Wiley & Sons Australia, Ltd.)

Published
2018
Full Text
View/download PDF

48. Chemotherapy Plus Bevacizumab as Neoadjuvant or Conversion Treatment in Patients with Colorectal Liver Metastases.

Author

García-Alfonso P, Cavanagh Podesta M, Muñoz Martín A, Blanco Codeisido M, Calvo A, Peligros I, Corcuera A, Belén Rúperez Blanco A, Custodio-Cabello S, López Trabada D, Martín M, and DE Ramón E

Subjects
Aged, Bevacizumab administration & dosage, Chemotherapy, Adjuvant methods, Colorectal Neoplasms drug therapy, Colorectal Neoplasms mortality, Disease-Free Survival, Female, Humans, Liver Neoplasms mortality, Male, Middle Aged, Neoadjuvant Therapy methods, Retrospective Studies, Treatment Outcome, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Colorectal Neoplasms pathology, Liver Neoplasms drug therapy, Liver Neoplasms secondary
Abstract

Aim: To evaluate the efficacy of chemotherapy plus bevacizumab as neoadjuvant or conversion treatment for colorectal liver metastases (CLM)., Patients and Methods: A retrospective chart review was carried out of 74 patients with CLM treated with neoadjuvant or conversion chemotherapy plus bevacizumab., Results: The overall response rate was 63.4%. An optimal morphological response by computed tomography was reported in 35% of patients. The rate of complete resection was 71.6%. Complete or major pathological response (pR) was attained in 58.2%. The median overall survival (OS) was not reached. Median progression-free (PFS) and relapse-free (RFS) survival were 14.6 and 8.7 months. Among patients reaching an optimal pR, median OS was not reached (p=0.08), and a trend towards longer RFS and PFS was seen., Conclusion: Neoadjuvant or conversion chemotherapy with bevacizumab is an active and tolerable option for CLM with minimal post-surgery complications. Optimal pR is associated with a longer OS and a trend for prolonged PFS and RFS., (Copyright© 2018, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.)

Published
2018
Full Text
View/download PDF

49. Bronchiolitis obliterans organizing pneumonia in patients with autoimmune rheumatic diseases.

Author

Rojas CM, Borella E, Palma L, Ragozzino S, De Ramón E, Gomez-Huelgas R, Punzi L, and Doria A

Subjects
Autoimmune Diseases diagnosis, Cryptogenic Organizing Pneumonia epidemiology, Cryptogenic Organizing Pneumonia therapy, Humans, Rheumatic Diseases diagnosis, Autoimmune Diseases complications, Cryptogenic Organizing Pneumonia complications, Cryptogenic Organizing Pneumonia diagnosis, Rheumatic Diseases complications
Abstract

Bronchiolitis obliterans organizing pneumonia (BOOP) is defined by buds of granulation tissue within lung distal airspaces. The diagnosis requires the histopathologic evidence of organizing pneumonia along with a suggestive clinical and radiographic pattern. This disorder is characterized by a good response to corticosteroids and an excellent prognosis. It can occur in association with a broad spectrum of clinical conditions or can be isolated, in this last case named cryptogenic organizing pneumonia. We searched for BOOP in patients with autoimmune rheumatic diseases (ARD) in the literature, and we found 32 well-documented cases. We reported here demographic features, manifestations, treatment and outcome of patients with BOOP associated with ARD. Notably, BOOP can be the presenting feature in some patients with ARD; thus, a close follow-up of patients with BOOP is recommended.

Published
2015
Full Text
View/download PDF

50. Analysis of ancestral and functionally relevant CD5 variants in systemic lupus erythematosus patients.

Author

Cenit MC, Martínez-Florensa M, Consuegra M, Bonet L, Carnero-Montoro E, Armiger N, Caballero-Baños M, Arias MT, Benitez D, Ortego-Centeno N, de Ramón E, Sabio JM, García-Hernández FJ, Tolosa C, Suárez A, González-Gay MA, Bosch E, Martín J, and Lozano F

Subjects
Alleles, Autoimmunity immunology, Case-Control Studies, Genetic Predisposition to Disease, Genotype, Humans, Lupus Erythematosus, Systemic complications, Lupus Erythematosus, Systemic immunology, Lupus Nephritis diagnosis, CD5 Antigens genetics, Haplotypes genetics, Lupus Erythematosus, Systemic genetics, Lupus Nephritis etiology, Lymphocyte Activation immunology, Polymorphism, Genetic genetics, T-Lymphocytes immunology
Abstract

Objective: CD5 plays a crucial role in autoimmunity and is a well-established genetic risk factor of developing RA. Recently, evidence of positive selection has been provided for the CD5 Pro224-Val471 haplotype in East Asian populations. The aim of the present work was to further analyze the functional relevance of non-synonymous CD5 polymorphisms conforming the ancestral and the newly derived haplotypes (Pro224-Ala471 and Pro224-Val471, respectively) as well as to investigate the potential role of CD5 on the development of SLE and/or SLE nephritis., Methods: The CD5 SNPs rs2241002 (C/T; Pro224Leu) and rs2229177 (C/T; Ala471Val) were genotyped using TaqMan allelic discrimination assays in a total of 1,324 controls and 681 SLE patients of Spanish origin. In vitro analysis of CD3-mediated T cell proliferative and cytokine response profiles of healthy volunteers homozygous for the above mentioned CD5 haplotypes were also analyzed., Results: T-cell proliferation and cytokine release were significantly increased showing a bias towards to a Th2 profile after CD3 cross-linking of peripheral mononuclear cells from healthy individuals homozygous for the ancestral Pro224-Ala471 (CC) haplotype, compared to the more recently derived Pro224-Val471 (CT). The same allelic combination was statistically associated with Lupus nephritis., Conclusion: The ancestral Ala471 CD5 allele confers lymphocyte hyper-responsiveness to TCR/CD3 cross-linking and is associated with nephritis in SLE patients.

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results